Common Supplement PQQ Found to Block Cancer-Driving Enzyme in Lymphoma Cells
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
389 articles in this topic
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
A sweeping 2025 review maps how gut, tumor, and systemic microbiomes promote or suppress cancer across every major tumor type.
A comprehensive review reveals how intracellular bacteria colonize cancer cells, fuel metastasis, and can be weaponized against tumors.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
A Nature study reveals lung tumors activate vagal nerves to drive sympathetic signaling that shuts down anti-tumor immunity.
Neuronal signals fuel small cell lung cancer via the vagus nerve and direct neuron-to-tumor synapses, opening new therapeutic targets.
A landmark screen of approved kinase inhibitors reveals 94% of cancer mutations are already targetable โ and uncovers surprising new drug uses.
A landmark genomic analysis of 50,000 tumors maps cancer-driving mutations across tumor types, revealing critical patterns that could reshape precision oncology.
A 13-year Italian cohort study finds ultra-processed foods don't raise breast cancer risk, but alcoholic beverages do.
A landmark RET-fusion lung cancer trial shows strong PFS gains but a puzzling OS signal โ revealing a critical flaw in how crossover trials are designed.
A pooled analysis of 2.5 million people links higher BMI and waist size to bladder cancer risk โ but only in males.